Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (abre nova janela)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Fonte‎: Cancer 2013;119(21):3784-7.

Indexado‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (abre nova janela)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (abre nova janela)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Fonte‎: Lancet 1989;334(8655):122-4.

Indexado‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (abre nova janela)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (abre nova janela)

Ben-Bassat I, Douer D, Ramot B.

Fonte‎: Eur J Haematol 1990;45(2):86-9.

Indexado‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (abre nova janela)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (abre nova janela)

Dean A, Tuffin P.

Fonte‎: J Pain Symptom Manage 1997;13(1):20-4.

Indexado‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (abre nova janela)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (abre nova janela)

Ford PA, Grant SJ, Mick R, Keck G.

Fonte‎: J Clin Oncol 2015;33(15):1674-9.

Indexado‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (abre nova janela)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (abre nova janela)

Garewal HS, Durie BG.

Fonte‎: Scand J Haematol 1985;35(5):497-500.

Indexado‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (abre nova janela)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (abre nova janela)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Fonte‎: Cancer 2006;107(1):136-40.

Indexado‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (abre nova janela)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (abre nova janela)

Marshall A, Li A, Drucker A, Dzik W.

Fonte‎: Hematol Oncol 2016;34(3):147-53.

Indexado‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (abre nova janela)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (abre nova janela)

Prokopchuk-Gauk O, Brose K.

Fonte‎: Cureus 2015;7(12):e428.

Indexado‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (abre nova janela)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (abre nova janela)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Fonte‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indexado‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (abre nova janela)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (abre nova janela)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Fonte‎: Hematol Oncol 2008;26(4):241-6.

Indexado‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (abre nova janela)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (abre nova janela)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Fonte‎: Am J Hematol 2006;81(9):720.

Indexado‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (abre nova janela)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (abre nova janela)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Fonte‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indexado‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (abre nova janela)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (abre nova janela)

Erduran E, Bahadir A, Mutlu M.

Fonte‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indexado‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (abre nova janela)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (abre nova janela)

Franchini M, Veneri D, Lippi G.

Fonte‎: Bone Marrow Transplant 2007;39(12):729-35.

Indexado‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (abre nova janela)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (abre nova janela)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Fonte‎: Am J Hematol 2002;69(3):219-22.

Indexado‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (abre nova janela)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (abre nova janela)

Hsieh A, Cheong I.

Fonte‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indexado‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (abre nova janela)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (abre nova janela)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Fonte‎: Haemostasis 1996;26 Suppl 1:159-64.

Indexado‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (abre nova janela)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (abre nova janela)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Fonte‎: Med Oncol 2010;27(1):16-9.

Indexado‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (abre nova janela)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (abre nova janela)

Vidarsson B, Önundarson PT.

Fonte‎: Thromb Haemost 2000;83(4):634-5.

Indexado‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (abre nova janela)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (abre nova janela)

Zver S, Andoljšek D, Černelč P.

Fonte‎: Eur J Haematol 2004;72(6):455-6.

Indexado‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (abre nova janela)

Management of bleeding complications of hematologic malignancies. (abre nova janela)

Green D.

Fonte‎: Semin Thromb Hemost 2007;33(4):427-34.

Indexado‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (abre nova janela)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (abre nova janela)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Fonte‎: Int J Lab Hematol 2013;35(4):457-9.

Indexado‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (abre nova janela)

Management of bleeding in patients with advanced cancer. (abre nova janela)

Pereira J, Phan T.

Fonte‎: Oncologist 2004;9(5):561-70.

Indexado‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (abre nova janela)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (abre nova janela)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Fonte‎: Haematologica 1997;82(5):584-7.

Indexado‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (abre nova janela)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (abre nova janela)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Fonte‎: Bull Cancer 2006;93(2):E7-12.

Indexado‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (abre nova janela)